Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children

Journal of Infectious Diseases

Volumn 206, Issue 8, 2012, Pages 1309-1318

  Weinberg, Adriana ^a   Song, Lin Ye ^b   Saah, Alfred ^c   Brown, Martha ^c   Moscicki, Anna B ^d   Meyer, William A ^e   Bryan, Janine ^c   Levin, Myron J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PLACEBO; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANTIBODY DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MUCOSAL IMMUNITY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; SINGLE DRUG DOSE; VACCINATION;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; CHILD; CROSS REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; MALE; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84866937055     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis489     Document Type: Article

References (47)

1. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24(Suppl 3):S3/11-25.
2. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572.
3. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190:37-45. (Pubitemid 38858402)
4. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500-10.
5. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006; 24(Suppl 3): S3/140-6.
6. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and typespecific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682-90. (Pubitemid 32826418)
7. Moscicki AB, Ellenberg JH, Crowley-Nowick P, Darragh TM, Xu J, Fahrat S. Risk of high-grade squamous intraepithelial lesion in HIVinfected adolescents. J Infect Dis 2004; 190:1413-21. (Pubitemid 39332180)
8. De Panfilis G, Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis 2002; 29:121-5. (Pubitemid 34219624)
9. Dolev JC, Maurer T, Springer G, et al. Incidence and risk factors for verrucae in women. AIDS 2008; 22:1213-9.
10. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010; 11:1048-56.
11. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24(Suppl 3):S3/1-10.
12. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: metaanalysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202:1789-99.
13. Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. N Engl J Med 2007; 356:1915-27.
14. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369:1693-702. (Pubitemid 46783792)
15. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
16. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-85.
17. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341:c3493.
18. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-14.
19. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65. (Pubitemid 39488060)
20. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 1996; 7:373-82. (Pubitemid 27380016)
21. Pinto LA, Castle PE, Roden RB, et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 2005; 23:3555-64. (Pubitemid 40602790)
22. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51.
23. Kreimer AeR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-51.
24. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197-204.
25. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246-53.
26. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15. (Pubitemid 36133838)
27. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011; 7:230-8.
28. Weinberg A, Pott GB. Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapy. Clin Diagn Lab Immunol 2003; 10:821-5. (Pubitemid 37129494)
29. Weinberg A, Song LY, Fenton T, et al. T cell responses of HIVinfected children after administration of inactivated or live attenuated influenza vaccines. AIDS Res Hum Retroviruses 2010; 26:51-9.
30. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:201-9. (Pubitemid 46340765)
31. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 2135-45. (Pubitemid 46393698)
32. Banura C, Franceschi S, Doorn LJ, et al. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 2008; 197:555-62. (Pubitemid 351321533)
33. Said HM, Ahmed K, Burnett R, Allan BR, Williamson AL, Hoosen AA. HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community-based microbicide study in Pretoria, South Africa. J Clin Virol 2009; 44:318-21.
34. Wong SC, Au TC, Chan SC, et al. Human papillomavirus DNA detection in menstrual blood from patients with cervical intraepithelial neoplasia and condyloma acuminatum. J Clin Microbiol 2010; 48:709-13.
35. Cuburu N, Kweon MN, Hervouet C, et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009; 183:7851-9.
36. Decroix N, Hocini H, Quan CP, Bellon B, Kazatchkine MD, Bouvet JP. Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens. Scand J Immunol 2001; 53:401-9. (Pubitemid 32275698)
37. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol 1979; 122:1892-8. (Pubitemid 9175317)
38. Rowhani-Rahbar A, Carter JJ, Hawes SE, et al. Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis 2009; 200:1452-5.
39. Seresini S, Origoni M, Lillo F, et al. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J Immunol 2007; 179:7176-83.
40. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol 2007; 178:7587-97. (Pubitemid 46898028)
41. Evans TG, Bonnez W, Rose RC, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183:1485-93. (Pubitemid 32417699)
42. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92:11553-7. (Pubitemid 26014152)
43. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
44. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85.
45. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35.
46. Draper E, Bissett SL, Howell-Jones R, et al. Neutralization of nonvaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 2011; 29:8585-90.
47. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3:109-15. (Pubitemid 47501028)